OKYO Pharma Limited
OKYOAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jul 13, 2026 | H.C. Wainwright | $5.00(+196%) | $1.69 | StreetInsider | |
| Jan 29, 2026 | H.C. Wainwright | Yi Chen | $7.00(+258%) | $1.96 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2025 |
| HC Wainwright& Co. | maintain | Buy | May 5, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 24, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 22, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 5, 2023 |
Earnings History
Next report: Dec 2, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 20, 2026 | $-0.15 | $-0.08 | — | — |
| Jan 30, 2026 | $-0.01 | $-0.07 | — | — |
| Jul 18, 2025 | $-0.04 | $-0.05 | — | — |
| Jan 29, 2025 | $-0.08 | — | — | — |
| Oct 2, 2024 | $-0.08 | — | — | — |
| May 13, 2024 | $-0.30 | — | — | — |
| Nov 29, 2023 | $-0.00 | — | — | — |
| Mar 31, 2023 | $-0.00 | — | — | — |
News
LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m.
OKYO Pharma Ltd (NASDAQ:OKYO) enrolled the first patients in its Phase 3 trial of urcosimod for neuropathic corneal pain, a chronic and often severe eye condition with no FDA-approved treatment, the company said on Tuesday. The registrational NEPTUNE study has activated its first US site, with additional sites opening throughout medical centers across the country, OKYO said.
LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).
LONDON and NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present and participate at upcoming ophthalmic conferences.
LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will present at Ophthalmology Futures Forum and in the 5th Annual ESCRS iNovation Day.
LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced participation at the Cantor Global Healthcare Conference being held September 9-11, 2026.